Company intelligence / Profile preview

NETRI

Lyon, Auvergne-Rhone-Alpes, France

Ownership: Private
Employees: ~30
Development stage: Other

Overview

NETRI’s platform is commercially available and used by pharmaceutical and academic partners for preclinical research, including pain quantification, neurotoxicity, and side effects assessment, especially in oncology. The technology is not clinically evaluated as a therapeutic product, but is actively used in R&D for drug screening and safety profiling[1][2][3][4][5][6][7][8][9].

Therapeutic areas: OncologyNeurologyOtherDermatology
Modalities: DeviceOrgan-on-chipBiologicSmall molecule
Industry: Non-Drug Biotech

Partnerships

CynbiomeAcademic partnersNational authorities in France

Beyond the preview

Go deeper on NETRI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NETRI.

Explore the full profile